1. Oncologist stabbed at Chennai govt hospital ‘by 26-year-old whose mother is undergoing cancer treatment’  The Indian Express
2. Video: Chennai man calmly walks away after stabbing doctor, wipes knife  India Today
3. Indian Medical Association condemns brutal attack on doctor in Chennai  The New Indian Express
4. Daylight assault on doctor inside Chennai hospital leaves medical fraternity in shock  The Hindu
5. 'No law and order': BJP, AIADMK attack ruling DMK after government doctor stabbed in Chennai  The Times of India

by: Darin IngelsMen with prostate cancer who take supplemental lycopene in addition to surgical removal of the testicles may experience less active disease, less bone pain, and live longer than those who only have surgical removal of the testicles, according to a new study in British Journal of Urology International (2003;92:375–8). This is exciting news for millions of men who have to undergo

Britain's Prince William has described the past year as "brutal" following cancer diagnoses for his wife and father. "Honestly, it's been dreadful," he said.

The United States has stopped research into new cancer treatments in Russia, Andrey Kaprin, oncologist at the Russian Ministry of Health, General Director of the National Medical Research Center of Radiology said. According to the expert, the United States independently refused to continue research into new cancer therapy. In particular, the US stopped cooperation on protocols. The corresponding decision of the United States has not affected cancer patients in Russia. On the contrary, domestic fundamental science was given a powerful impetus for development, he noted. "The most important thing that we have come to realise is that we need to create our own,” said the oncologist.

Source: Dr. David Nierengarten 11/07/2024

TScan Therapeutics Inc. (TCRX:NASDAQ) Phase 1 ALLOHA study, evaluating its lead therapeutic candidates TSC-100 and TSC-101 in hematologic malignancies, showed patients continuing to have a positive response after one year, reported Wedbush analyst Dr. David Nierengarten in a Nov. 5 research note. TSC-100 and TSC-101 are T-cell receptor-engineered T-cell therapies (TCR-Ts).

"We see a catalyst-rich next few months ahead with data building in prominence on stock impact," Nierengarten wrote.

87% Return Potential

Wedbush has a US$10 per share target price on the Massachusetts-based biotech, trading at the time of the report at about US$5.36 per share, noted the analyst. The difference between these figures implies an 87% return potential for investors.

TScan Therapeutics remains rated Outperform.

Durability of Response Data

Nierengarten presented the clinical trial's latest results. As of the July 8, 2024 data cutoff date, in Phase 1 of ALLOHA, 16 patients with hematologic tumors had been administered TSC-100 or TSC-101, and 11 patients had been given a placebo. Median follow-ups had occurred at 5.8 months and 5.3 months, respectively.

At the time, none of the patients in the treatment arm had had a relapse. In the control arm, however, three, or 27% of, the 11 patients had, and the median time to relapse was 159 days. The analyst explained that this is typical for patients receiving a hematopoietic stem cell transplant after reduced-intensity conditioning.

One year out from treatment, five patients were evaluable, and all remained relapse free and minimal residual disease negative at the time. These data underscore the durability of response to this TCR-T treatment, Nierengarten commented. Its safety profile was shown to be favorable still, with no patients experiencing dose-limiting toxicities or adverse events associated with allogeneic hematopoietic cell transplantation.

"Enrollment continues in dose expansion cohorts, and results could support a registrational trial as early as 2025, pending regulatory feedback," Nierengarten wrote.

On the Horizon

TScan Therapeutics has several catalysts related to its clinical programs on the horizon, which Nierengarten listed.

On Nov. 8 and 9, the company will present preclinical data in the poster sessions at the annual Society for Immunotherapy of Cancer meeting. One poster will show in vitro combinatorial data for T-Plex, TScan's cellular therapy for treating solid tumors. It is comprised of two to three different TCR-Ts that target different tumor antigens on different human leukocyte antigen (HLA) types.

A second poster will detail the expansion of ImmunoBank, the biotech's diverse bank of therapeutic T-cell receptors (TCRs) that recognize diverse targets and are associated with multiple HLA types. The third will depict development of a target agnostic platform to evaluate how TCR-Ts affect primary human tissues.

On Dec. 9, TScan Therapeutics will present updated one-year data from ALLOHA, at the American Society for Hematology Annual Meeting in December.

By year-end, the biotech will announce initial data from administering singleplex therapy, cell therapy engineered using a single TCR, to patients with solid tumors. This treatment is being given to establish safety before administering multiplex therapy, cell therapy engineered from multiple TCRs.

In 2025, TScan Therapeutics will provide long-term duration of response data for multiplex therapy in solid tumors and will potentially commence a registrational trial for TSC-100 and TSC-101.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, TScan Therapeutics Inc., November 5, 2024

Analyst Certification We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

Company Specific Disclosures This information is subject to change at any time. 1. WS makes a market in the securities of TScan Therapeutics, Inc.. 6. WS is acting as a financial advisor for TScan Therapeutics, Inc..

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: TCRX:NASDAQ, )

Yiqun Han recognized for expertise in breast cancer research and treatment

MTI will hold its fifth annual "Teeing for Ta-Tas" charity golf tournament at Orlando's Rosen Shingle Creek Golf Resort to support AdventHealth breast cancer research on October 30, 2021, at 8:00 AM.

NRC and CCAB invest over $1M to advance innovative therapies first discovered at UofTToronto, ON – An innovative collaboration between government, industry, and academia aims to accelerate the development of cancer treatments in Canada. The National Research Council of Canada (NRC) and the Toronto-based Centre for the Commercialization of Antibodies and Biologics (CCAB) have put […]

Computer games help children overcome pain from cancer treatment

The Ipswich legend and former Scotland manager says he is feeling optimistic after his initial treatment.

Discovery Health Medical Scheme's (DHMS) 2023 cancer claims payouts were almost 19% higher than the previous year though the scheme says screening rates in South Africa have mostly returned to pre-pandemic levels.

Title: Breast Cancer Treatment Effects on Sex Life a Hidden Burden
Category: Health News
Created: 8/8/2022 12:00:00 AM
Last Editorial Review: 8/9/2022 12:00:00 AM

Title: Hopes Dashed for Rare Bone Cancer Treatment
Category: Health News
Created: 8/26/2016 12:00:00 AM
Last Editorial Review: 8/26/2016 12:00:00 AM

Stem cells made in the lab may one day aid cancer treatment by reducing our reliance on donors

People with cancer may have understandable reasons to follow Australian supermodel Elle Macpherson in declining chemotherapy, but the odds aren’t in their favour, warns Elle Hunt

Highlights: Protein homeostasis is critical for physiology of cell and their functioning PROTACs have the abilit

Newly discovered targets may hold the key to effectively treating glioblastoma, a deadly form of brain cancer. These targets were identified by screening

Digestive tract cancer is one of the life-threatening tumor conditions among all cancers. Using endoscopic diagnostic methods, the tumor can be detected and treated at earlier stages (!--ref1--).

The long-term risks of prostate cancer treatment, including adverse effects and complications, can persist for years. A recent study published in iJAMA

Decitabine, a medlinkprostate cancer/medlink drug, that inhibits DNA methylation, effectively cuts tumor growth in prostate cancer with neuroendocrine features or loss of the gene RB1.

New report outlines long-term risks of prostate cancer treatment, highlighting potential impacts on quality of life and need for informed decisions.

Researchers have developed a non-invasive method to identify a possible cause of high blood pressure by drastically reducing radiation exposure, as suggested by a recent study.

Comprehensive computational pipeline that integrates molecular and genetic analyses of tumors, along with T-cell targets, to design personalized cancer

Animal rescued by Forest dept. diagnosed with mast cell tumour

Few relationships would be immune to the pressures wrought by their ordeal: the strain of caring for their desperately sick child, their brief life as fugitives, the draining legal battles.

Few relationships would be immune to the pressures wrought by their ordeal: the strain of caring for their desperately sick child, their brief life as fugitives, the draining legal battles.

Throughout history people have turned to nature for relief from illnesses and this remains true today. With new technologies, researchers have an even greater ability to identify natural products that may lead to treatment or prevention of a wide range of health problems.

Florida Cancer Specialists & Research Institute LLC (FCS), an oncology group headquartered in Fort Myers, Florida, was charged with conspiring to allocate medical and radiation oncology treatments for cancer patients in Southwest Florida, the Department of Justice announced.  This charge is the first in the department’s ongoing investigation into market allocation in the oncology industry.

The present invention relates to novel isocyanate and isothiocyanate compounds, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans and animals. The novel isocyanate and isothiocyanate compounds are distinguished, as compared with the known isocyanate and isothiocyanate compounds, by improved therapeutical breadth, i.e. fewer side effects while having high anti-tumor activity.

Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.

There is provided an ultrasonic cancer treatment enhancer and cell killer that can significantly improve the effect of treating cancer by ultrasonic irradiation while ensuring a high level of safety. The ultrasonic cancer treatment enhancer and cell killer comprise metal semiconductor particles and can be activated upon ultrasonic irradiation to kill or destruct cancer cells.

The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.

Under normal circumstances, a cancer diagnosis can be life altering. But with cases of COVID-19 straining medical systems across the state and with new expectations for social distancing in place, the way in which cancer treatment is received and supported is creating new challenges for some Iowans.

Cancer patients in the remote Pilbara will soon be trialling chemotherapy via video link, saving them a 1,500-kilometre trip for life-saving treatment.

DAILY BRIEFING: The family of three-year-old Eleanor Oakley, which has been fundraising so the young girl can travel to the US to receive cancer treatment, reaches its $300,000 target.

"If you’re gonna do it, get the good stuff."

The post MEGADETH's Dave Mustaine Said Cannabis Helped With His Cancer Treatments appeared first on Metal Injection.

In a British cohort, 30% of patients who had survived childhood cancer had died within 45 years of diagnosis; only 6% were expected to have died. 51% had developed a new primary cancer, but a 26% died of cardiovascular disease - thought to be caused by their treatment. Consequently, efforts to reduce long term mortality have focused on reducing...

Background:

We assessed the ability to supplement existing epidemiologic/etiologic studies with data on treatment and clinical outcomes by linking to publicly available cancer registry and administrative databases.

Kilmer, a follower of Christian Science calls it: the “suggestion of throat cancer.”

The 60-year-old actor has children Jack, 24, and Mercedes, 28, from his marriage to ex-wife Joanne Whalley and when Val

NHS England has expanded access to targeted hormone therapies for advanced prostate cancer

Hope Cancer Institute, a cancer treatment facility in Kansas, and Dr. Raj Sadasivan, the owner of Hope Cancer Institute, have agreed to pay $2.9 million to resolve allegations that they violated the False Claims Act by submitting claims to Medicare, Medicaid and the Federal Employee Health Benefits Program for drugs and services that were not provided to beneficiaries.

Highlights: Boron can now be retained within cancer cells using a novel method Trapping boron within ca